Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MGN1601 in advanced renal cell carcinoma (ASET)
NCT01265368Phase 2Completed
- Sponsor
- Mologen AG
- Start
- Nov 2010
- Primary completion
- Aug 2013
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of MGN1601 in renal cell carcinoma (RCC), sponsored by Mologen AG. Started Nov 2010; status: completed.
02
Drugs
MGN1601
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01265368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01265368.